.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
UBS
Chinese Patent Office
Dow
Deloitte
McKesson
Covington
Farmers Insurance
Queensland Health
Daiichi Sankyo

Generated: December 18, 2017

DrugPatentWatch Database Preview

OPTISON Drug Profile

« Back to Dashboard

Which patents cover Optison, and when can generic versions of Optison launch?

Optison is a drug marketed by Ge Healthcare and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in twenty-seven countries and nine supplementary protection certificates in seven countries.

The generic ingredient in OPTISON is albumin human. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the albumin human profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge HealthcareOPTISONalbumin humanINJECTABLE;INJECTION020899-001Dec 31, 1997RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OPTISON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge HealthcareOPTISONalbumin humanINJECTABLE;INJECTION020899-001Dec 31, 1997► Subscribe► Subscribe
Ge HealthcareOPTISONalbumin humanINJECTABLE;INJECTION020899-001Dec 31, 1997► Subscribe► Subscribe
Ge HealthcareOPTISONalbumin humanINJECTABLE;INJECTION020899-001Dec 31, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OPTISON

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,620,404 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media► Subscribe
5,558,854 Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas► Subscribe
6,156,292 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media► Subscribe
5,393,524 Methods for selecting and using gases as ultrasound contrast media► Subscribe
6,875,420 Method of ultrasound imaging► Subscribe
5,573,751 Persistent gaseous bubbles as ultrasound contrast media► Subscribe
5,558,094 Methods for using persistent gases as ultrasound contrast media► Subscribe
5,409,688 Gaseous ultrasound contrast media► Subscribe
5,666,526 Method and system for supporting scrollable, updatable database queries► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OPTISON

Country Document Number Estimated Expiration
Norway313577► Subscribe
Japan2001026554► Subscribe
Denmark0605477► Subscribe
Portugal100867► Subscribe
Greece3033908► Subscribe
Singapore54121► Subscribe
HungaryT68083► Subscribe
Norway940956► Subscribe
World Intellectual Property Organization (WIPO)9305819► Subscribe
Australia3995997► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OPTISON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
41/2009Austria► SubscribePRODUCT NAME: PACLITAXEL ALBUMIN
00673Netherlands► SubscribePRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
2014000065Germany► SubscribePRODUCT NAME: PACLITAXEL ALS AN ALBUMIN GEBUNDENE NANOPARTIKEL-FORMULIERUNG; REGISTRATION NO/DATE: K(2013)9835 20131220
0673Netherlands► SubscribePRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
0961612/01Switzerland► SubscribePRODUCT NAME: PACLITAXELUM-ALBUMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63182 26.08.2014
/2014Austria► SubscribePRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230
2014 00034Denmark► SubscribePRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: C(2013)9835 20131220
8 50005-2014Slovakia► SubscribePRODUCT NAME: PAKLITAXEL VO FORME NANOCASTIC VIAZANYCH NA ALBUMIN; REGISTRATION NO/DATE: EU/1/07/428/001 - EU/1/07/428/002 20131230
C0050France► SubscribePRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE: EU/1/07/428/001 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Johnson and Johnson
Cipla
Medtronic
Citi
Daiichi Sankyo
Dow
AstraZeneca
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot